Currently the compendial method for quantifying subvisible particles equal to or greater than 10 µm and 25 µm uses light obscuration (LO), which is internationally harmonized in the U.S., European, and Japanese Pharmacopoeia. However, numerous reports have indicated that subvisible particles smaller than 10 µm could elicit immune responses.
Pictured: intravenous immunoglobulin as imaged by the FlowCam 8000 imaging particle analyzer and the MFI.
The Food and Drug Administration (FDA) has published guidance on the immunogenicity assessment for therapeutic protein products, wherein they recommend the assessment of subvisible particles below 10 µm. The FDA recommends the characterization of subvisible particles during the product life cycle using orthogonal methods, of which flow imaging (FI) is one.
In this study, the size and count of 3 different subvisible particle preparations were analyzed using LO and FI (MFI and FlowCam) in 12 laboratories to clarify the consistency of subvisible particles and the analytical performance of each instrument. Three types of subvisible particles were shared across 12 laboratories and analyzed for their sizes and counts. Results were compared between the methods, FI and LO, inter-laboratories, and inter-instruments (FlowCam and MFI).
It was determined that FI may be a viable alternative to LO, as it yields a large number of detailed morphological properties of subvisible particles. FI has been shown to be more sensitive than LO for highly transparent particles such as proteins. Moreover, FlowCam provided a relatively higher number of particles compared with MFI, and consistent results were obtained using the instrument from the same manufacturer in all three samples.
Read the full article
Learn why it's important to characterize biotherapeutics with orthogonal techniques. What happens when you combine flow imaging with light obscuration in a single instrument?
